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Introduction
Human adenovirus (HAdV) can cause serious morbidity in immunocompromised patients, in particular in pediatric patients after allogeneic stem cell transplantation (alloSCT), and progression to disseminated HAdV disease is associated with high mortality (1) (2) (3) (4) (5) . Efficacy of antiviral agents such as ribavirin and cidofovir has not been proven in controlled trials yet, and administration is limited by toxicity. It has been demonstrated that reconstitution of HAdVspecific T cells is essential to control HAdV infection after alloSCT (5) (6) (7) (8) (9) . Manipulation of immune reconstitution by adoptive transfer of donor-derived HAdV-specific T cells may therefore be an effective strategy to provide short-and long-term antiviral protection.
In healthy individuals, low frequencies of T cells recognizing target cells infected with
HAdV or loaded with HAdV lysate have been reported (10) (11) (12) . The majority of HAdV-specific T cells was CD4+, although HAdV-specific CD8+ T cells could also be detected. Further characterization demonstrated that most HAdV-specific T cells recognized major capsid proteins, predominantly the abundant HAdV hexon protein (13) (14) (15) . Only recently, a number of immunodominant CD8+ and CD4+ epitopes of HAdV hexon have been defined (14) (15) (16) (17) (18) (19) . Since these epitopes are largely conserved, specific T cells were shown to be cross-reactive towards HAdV serotypes from different HAdV subgroups, and may therefore provide protection against a wide range of HAdV serotypes. HAdV hexon-specific T cells have been reported to be detectable in 72% of healthy donors, but may be present at very low frequencies in the remaining donors (20) .
In alloSCT recipients, higher frequencies of HAdV-specific T cells have been detected after clearance of HAdV infection, but epitope specificity of these responses has not been further characterized (7) (8) (9) . Furthermore, mainly CD4+ T cells and no CD8+ T cells specific for HAdV were detected. Since HAdV-specific CD4+ T cells are capable to directly lyse HAdV infected 4 target cells, the relative contribution of HAdV-specific CD4+ and CD8+ T cells in protection from HAdV disease after alloSCT remains to be elucidated (21;22) .
For the generation of donor-derived HAdV-specific T cell lines for clinical application, peripheral blood has been stimulated with HAdV antigens or HAdV transduced antigenpresenting cells, resulting in enrichment of either CD4+ or CD8+ T cells specific for HAdV (20;23-29) . Although alloreactivity was reduced using these strategies, the frequency of HAdVspecific T cells in the cell lines was not determined or was limited, even when IFN!-based isolation steps were included.
In this study, we demonstrate that CD8+ and CD4+ T cell responses against HAdV hexon epitopes were associated with clearance of HAdV infection in pediatric and adult patients after alloSCT, providing a rationale for HAdV hexon-specific adoptive immunotherapy. For the generation of clinical grade combined CD8+ and CD4+ HAdV-specific T cell lines, efficient activation of both CD8+ and CD4+ HAdV-specific T cells by stimulation with an HAdV hexon protein-spanning peptide pool was followed by IFN!-based isolation. Cultured T cell lines derived from all healthy donors tested contained high frequencies of CD8+ and CD4+ T cells specific for multiple HAdV hexon epitopes, and efficiently lysed HAdV-infected target cells. The adoptive transfer of these donor-derived HAdV hexon-specific T cell lines may be used for treatment of disseminated HAdV disease after alloSCT.
Design and Methods

Donor and patient cells
Donor and patient cells were obtained after informed consent, with approval from the local institutional review board. Peripheral blood mononuclear cells (PBMC) were obtained after Ficoll-Isopaque separation. Measurement of HAdV DNA in patient plasma was performed by RQ-PCR as previously described (30) . Fibroblasts were cultured from skin biopsies in DMEM with 10% fetal calf serum (Lonza, Basel, Switzerland).
HAdV antigens
Peptides were derived from the HAdV serotype 5 hexon protein (AP_000211). MHC I restricted (17) . A titrated stock of HAdV serotype 5 was produced as previously described (8) .
Flow cytometry
Cells were stained with FITC-labeled CD3, CD4, CD27, CD28 (BD Biosciences, San Jose, CA, USA), CD45RO (Caltag, Burlingame, CA, USA), CD62L (BenderMedSystems, Vienna, Austria), CCR7 (R&DSystems, Minneapolis, MN, USA), PE-labeled CD28 (BD), CD45RA, DOI: 10.3324/haematol.2010.022947 6 CD40L (Beckman Coulter, Fullerton, CA, USA), CCR7 (R&DSystems), PerCP-labeled CD8 (BD), APC-labeled CD4 (Beckman Coulter), CD45RA, CD45RO, and IFN! (BD) monoclonal antibodies (mAbs). PE-and APC-labeled HAdV 5 hexon peptide-MHC tetramers were produced as described previously (31) . Fluorescent events were analyzed for each sample using a FACSCalibur and Cellquest software (BD). The limit of detection was defined as a cluster of at least 10 specific events, after correction for background events in negative control samples. Netherlands) for distinction in FACS analysis as previously described (32) . Stimulator cells were loaded overnight with 10 -6 M HAdV 5 hexon peptides and the T cells were incubated with stimulator cells for 4 hours with 10 !g/ml BFA. After stimulation, cell-surface staining with mAbs was performed, followed by intracellular staining as previously described (33) . 
Cytotoxicity assay
Standard 51 Cr release assay was performed as described previously (34) . Briefly, fibroblasts 
Results
HAdV hexon-specific T cells in healthy donors
To analyze the HAdV hexon-specific T cell response in PBMC from healthy adult donors, we determined frequencies of CD8+ and CD4+ T cells specific for HAdV serotype 5 hexon epitopes.
Analysis of the kinetics of IFN! production after stimulation showed maximal IFN! production 4 hours after stimulation with the HAdV 5 hexon protein-spanning 15-mer peptide pool, which was similar for CMV-specific T cells as described recently (33) . Therefore, cumulative intracellular IFN! staining was measured 6 hours after stimulation with the hexon 15-mer peptide pool. These data show that low frequencies of HAdV hexon-specific CD4+ T cells were detected directly ex vivo in peripheral blood from 81% of healthy adults, while hexon-specific CD8+ T cells could be detected directly ex vivo in 38% of donors. To determine whether the HAdV hexon-specific T cell response was below the threshold of detection in the donors where no HAdV hexon-specific responses could be detected directly ex vivo, PBMC were stimulated for 1 week with HAdV hexon peptide pool and IL-2 for specific expansion. Subsequently, restimulation with HAdV hexon peptide pool followed by intracellular IFN_ staining showed hexon-specific CD8+ and CD4+ T cells in PBMC from all healthy adults tested (data not shown),
indicating that low frequencies of HAdV hexon-specific T cells were present in PBMC from all healthy adults.
HAdV-specific T cell response in alloSCT recipients
We next analyzed whether HAdV hexon-specific T cell responses were associated with clearance of HAdV infection in alloSCT recipients, using the same method as for the healthy individuals.
From previously described cohorts of patients, we selected 7 pediatric and 6 adult patients, who
developed HAdV viremia as determined by positive HAdV DNA plasma load, and subsequently showed spontaneous resolution of disseminated infection (4;8). HAdV-specific T cell responses could not be analyzed in patients who deceased from HAdV viremia, since only for a few patients peripheral blood samples were available and the lymphocyte numbers in these samples were too low for analysis. Peripheral blood samples obtained during positive HAdV plasma load were available for 10 patients, and peripheral blood samples obtained after resolution of HAdV viremia were available for all 13 patients. During HAdV viremia hexon-specific CD8+ T cells could not be detected directly ex vivo and hexon-specific CD4+ T cells were detected in 2 patients ( Figure   2A ). After 1 week of culture with the hexon peptide pool and IL-2 for specific expansion, the presence of low frequencies of hexon-specific CD4+ T cells was observed in 5 patients, while no hexon-specific CD8+ T cells could be detected. Following resolution of HAdV viremia, direct intracellular staining showed hexon-specific CD8+ T cells in 7 patients, and hexon-specific CD4+
T cells in all patients ( Figure 2B ). After 1 week culture of these cells with hexon peptides and IL-2, both hexon-specific CD8+ and CD4+ T cells were shown to be present in PBMC from 12 of the 13 patients. In 4 patients, part of hexon-specific CD8+ T cells were directed against previously described epitopes, as detected by peptide-MHC tetramer staining after expansion
(data not shown).
A more detailed analysis of development of HAdV-specific T cell responses is shown for 5 patients, of whom multiple peripheral blood samples were available ( Figure 3 ). During HAdV viremia, direct intracellular IFN! staining upon hexon peptide pool stimulation showed no or low frequencies of hexon-specific CD8+ or CD4+ T cells in these patients. After clearance of the HAdV plasma load, high frequencies up to 30% of CD8+ T cells and 16% of CD4+ T cells producing IFN! upon hexon peptide pool stimulation appeared in peripheral blood. The hexonspecific T cells emerged directly after resolution of HAdV viremia in most patients, although proliferation of high frequencies of hexon-specific T cells was shown to continue for several months after clearance of the HAdV plasma load in pediatric patient 1 ( Figure 3A) . The relation between the development of hexon-specific T cells and control of HAdV infection was illustrated by the minor HAdV reactivation at day 152 after transplantation in pediatric patient 2, which was followed by an increase in frequencies of HAdV hexon-specific CD8+ and CD4+ T cells and concomitant viral clearance ( Figure 3C ). These results demonstrate that a coordinated CD8+ and CD4+ T cell response specific for HAdV hexon epitopes was associated with clearance of HAdV infection in both pediatric and adult patients following alloSCT.
Generation of HAdV hexon-specific CD8+ and CD4+ T cell lines
As the presence of CD4+ as well as CD8+ HAdV hexon-specific T cells was associated with viral clearance after alloSCT, a clinical grade protocol was developed for the generation of HAdV hexon-specific T cell lines containing both T cell subsets. PBMC from healthy adult donors were stimulated with the hexon peptide pool, and IFN!-secreting cells were isolated and cultured with autologous feeders and IL-2. The data of a representative T cell line generated are shown ( Figure   4A -C). Before enrichment, low frequencies of HAdV-specific T cells were detected in PBMC ( Figure 4A ). In the T cell line generated from the enriched cell population ( Figure 4B ), 74% of CD8+ T cells (58% of total cells) were directed against the MPN/HLA-B35 epitope (19) .
Restimulation of the T cell line with autologous EBV-LCL loaded with the hexon peptide pool induced specific IFN! production by 94% of CD8+ T cells, indicating that additional hexon CD8+ epitopes were recognized. Furthermore, hexon-specific IFN! production upon restimulation was observed by 91% of CD4+ T cells. Only low frequencies of hexon-specific T cells could be detected in the IFN!-depleted fraction ( Figure 4C) . Results from all 6 donors are summarized (Table 1) . HAdV-specific T cell lines could be generated from donors with relatively high frequencies as well as from donors with low or undetectable frequencies of hexon-specific 
Characterization of HAdV hexon epitopes recognized
To determine the repertoire of HAdV hexon epitopes recognized by HAdV-specific T cell lines, staining was performed with peptide-MHC tetramers covering all known HAdV hexon CD8+ epitopes restricted by prevalent MHC class I molecules. CD8+ T cell populations specific for 7 previously described hexon epitopes were detected in the HAdV-specific T cell lines derived from 6 healthy donors (Supplemental Table 1 ). Analysis of specific IFN! production by CD8+ T cells upon restimulation with separate hexon overlapping 30-mer peptides showed recognition of 4 additional hexon peptides by the HAdV-specific T cell lines, of which 2 were recognized by CD8+ T cells from 2 different donors (Supplemental Table 1 Table 1 ). Both previously described and newly identified hexon CD8+ epitopes were largely conserved between different HAdV species (Supplemental Table 2 ).
Furthermore, CD4+ T cells in all T cell lines recognized multiple hexon 30-mer peptides, indicating a broad specificity which included conserved HAdV hexon regions. These data demonstrate that HAdV-specific T cell lines generated by IFN!-based isolation after hexon peptide pool stimulation recognized multiple CD8+ and CD4+ HAdV hexon epitopes, including both known and novel epitopes, thereby exploiting the full donor HLA repertoire.
Discussion
Based on our observation that resolution of HAdV viremia coincided with appearance of a coordinated CD8+ and CD4+ HAdV hexon-specific T cell response in patients following alloSCT, we developed a method for generation of CD8+ and CD4+ T cell lines with high and defined specificity for HAdV hexon for adoptive immunotherapy. HAdV-specific CD8+ T cells have been detected before in healthy adults and in patients following alloSCT (7;15;18-20;27 ).
Our study further shows a kinetic association between HAdV-specific CD8+ T cell responses and clearance of HAdV infection in alloSCT recipients.
Since in previous studies predominantly HAdV-specific CD4+ T cells were detected in peripheral blood from healthy individuals, and since these CD4+ T cells showed direct cytotoxic capacity, the role of CD8+ T cells in protection from HAdV disease has been questioned (1;10;12;17;21;22) . In this study, HAdV hexon-specific T cells were detected with high sensitivity using peptide-MHC tetramer staining and intracellular cytokine staining following stimulation with a HAdV hexon peptide pool. Using these methods, low frequencies of HAdV hexon-specific CD8+ and CD4+ T cells were detected directly ex vivo in peripheral blood from 38% and 81% of healthy adults, respectively. Subsequently, activation of HAdV hexon-specific T cells with the hexon peptide pool followed by IFN!-based isolation allowed rapid expansion of both CD8+ and CD4+ T cells specific for HAdV hexon epitopes from all healthy donors tested.
These data suggest that coordinated responses of CD8+ and CD4+ T cells specific for HAdV hexon epitopes contribute to control of HAdV infection in healthy individuals, and persist as memory T cells afterwards, which is similar to T cell responses described against most other viral infections.
While the development of HAdV-specific T cell responses in patients after alloSCT has previously been shown to be associated with protection from HAdV disease, only HAdV-specific CD4+ T cells, and no HAdV-specific CD8+ T cells have been detected (7) (8) (9) . To further Despite the low to undetectable frequencies of HAdV hexon-specific T cells in healthy individuals, using HAdV hexon peptide pool stimulation followed by IFN!-based isolation, highly specific T cell lines could be generated from all donors tested. In contrast to previous studies, we demonstrated high and defined specificity of the T cell lines for HAdV hexon epitopes (median 87% of CD8+ T cells and 70% of CD4+ T cells). The risk of graft-versus-host disease may be determined by the repertoire of non-HAdV-specific T cells, and therefore by the absolute number of non-HAdV-specific T cells isolated from donor PBMC. The very low numbers of non-HAdV-specific T cells isolated using this method are assumed to result in a minimal risk of graft-versus-host disease. This assumption was supported by the absence or very low levels of residual alloreactive capacity of the HAdV-specific T cell lines generated.
Furthermore, no adverse events associated with administration of HAdV-or cytomegalovirusspecific T cell lines generated by IFN!-based isolation have been reported (23;35;36) . 
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